Research programme: malaria vaccine - Maxygen

Drug Profile

Research programme: malaria vaccine - Maxygen

Alternative Names: Maxy-678; Maxy-Malaria

Latest Information Update: 10 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxygen
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 10 Jun 2013 Discontinued - Preclinical for Malaria in USA (Parenteral)
  • 18 Sep 2008 This malaria vaccine programme is available for licensing (
  • 20 Jun 2006 No development reported - Preclinical for Malaria in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top